Trinity Biotech PLC - רווח נקי למניה בארבעת הרבעונים האחרונים TRIB

Trinity Biotech plc (TRIB) is transforming its core business through the acquisition of glucose monitoring startups. This GURU.Markets chart illustrates the year-over-year change in EPS (TTM), where the figure settled at 39.60. While leadership in rapid infection diagnostics ensures a steady cash flow, geopolitical instability and raw material supply chain disruptions could increase operating expenses for the Irish manufacturer.

This indicator measures the earnings per share trend over a rolling year, reflecting the business's ability to scale net income relative to previous periods. By analyzing the annual EPS TTM delta, an investor assesses the cost management efficiency of Trinity Biotech plc (TRIB), where profit stability depends directly on the optimization of complex reagent delivery logistics to laboratories and pharmacies.